Kezar Life Sciences, Inc. KZR
We take great care to ensure that the data presented and summarized in this overview for Kezar Life Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KZR
View all-
Suvretta Capital Management, LLC New York, NY7.17MShares$5.02 Million0.28% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$3.52 Million0.17% of portfolio
-
Black Rock Inc. New York, NY4.62MShares$3.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$2.17 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.05MShares$1.44 Million0.29% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.93MShares$1.35 Million0.04% of portfolio
-
Acadian Asset Management LLC Boston, MA1.79MShares$1.25 Million0.01% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.76MShares$1.23 Million0.23% of portfolio
-
Geode Capital Management, LLC Boston, MA1.37MShares$961,5820.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.34MShares$936,6510.0% of portfolio
Latest Institutional Activity in KZR
Top Purchases
Top Sells
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Insider Transactions at KZR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2023
|
Morningside Venture Investments LTD |
SELL
Bona fide gift
|
Direct |
3,500,000
-64.24%
|
-
|
|
Jul 20
2023
|
Christopher J. Kirk CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,950
+10.19%
|
$0
$0.9 P/Share
|
|
Feb 06
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
40,000
-0.73%
|
$240,000
$6.88 P/Share
|
|
Feb 03
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
25,000
-0.45%
|
$175,000
$7.15 P/Share
|
|
Feb 02
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
50,000
-0.9%
|
$350,000
$7.19 P/Share
|
|
Feb 01
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
40,000
-0.71%
|
$240,000
$6.95 P/Share
|
|
Jan 31
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
30,000
-0.53%
|
$210,000
$7.08 P/Share
|
|
Jan 30
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
30,000
-0.53%
|
$180,000
$6.91 P/Share
|
|
Jan 25
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
50,000
-0.88%
|
$300,000
$6.85 P/Share
|
|
Jan 24
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
80,000
-1.38%
|
$480,000
$6.98 P/Share
|
|
Jan 23
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
80,000
-1.36%
|
$480,000
$6.81 P/Share
|
|
Jan 17
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
6,114
-0.1%
|
$36,684
$6.79 P/Share
|
|
Jan 13
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
1,971
-0.03%
|
$13,797
$7.15 P/Share
|
|
Jan 12
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
5,000
-0.08%
|
$30,000
$6.77 P/Share
|
|
Jan 06
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
3,000
-0.05%
|
$18,000
$6.89 P/Share
|
|
Jan 05
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
12,162
-0.21%
|
$72,972
$6.97 P/Share
|
|
Jan 04
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
30,000
-0.51%
|
$210,000
$7.17 P/Share
|
|
Jan 03
2023
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
500
-0.01%
|
$3,500
$7.1 P/Share
|
|
Dec 29
2022
|
Morningside Venture Investments LTD |
SELL
Open market or private sale
|
Direct |
25,000
-0.42%
|
$175,000
$7.1 P/Share
|
|
Nov 10
2022
|
John Franklin Fowler CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+6.41%
|
$0
$0.9 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 49K shares |
|---|
| Bona fide gift | 3.5M shares |
|---|